CY1126141T1 - Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης - Google Patents
Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπηςInfo
- Publication number
- CY1126141T1 CY1126141T1 CY20231100357T CY231100357T CY1126141T1 CY 1126141 T1 CY1126141 T1 CY 1126141T1 CY 20231100357 T CY20231100357 T CY 20231100357T CY 231100357 T CY231100357 T CY 231100357T CY 1126141 T1 CY1126141 T1 CY 1126141T1
- Authority
- CY
- Cyprus
- Prior art keywords
- free base
- crystal form
- base hydrate
- lorlatinib free
- lorlatinib
- Prior art date
Links
- 239000012458 free base Substances 0.000 title abstract 2
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title abstract 2
- 229950001290 lorlatinib Drugs 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 150000004678 hydrides Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Η εφεύρεση αυτή αφορά σε μια κρυσταλλική μορφή του υδρίτη ελεύθερης βάσης του (10R)-7-αμινο-12-φθορο-2,10,16-τριμεθυλο-15-οξο-10,15,16,17-τετραϋδρο-2Η-8,4-(μεθενο)πυραζολο[4,3-h][2,5,11] βενζοξαδιαζακυκλο-τετραδεκινο-3-καρβονιτριλίου (λορλατινίμπη) (Μορφή24). Η εφεύρεση αυτή αφορά επίσης σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τη μορφή 24, καθώς και σε μεθόδους χρήσης της μορφής 24 και όμοιων συνθέσεων στη θεραπεία της ανώμαλης κυτταρικής αύξησης, όπως είναι ο καρκίνος, σε ένα θηλαστικό.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US201862727734P | 2018-09-06 | 2018-09-06 | |
| PCT/IB2018/057735 WO2019073347A1 (en) | 2017-10-10 | 2018-10-04 | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1126141T1 true CY1126141T1 (el) | 2023-11-15 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20231100357T CY1126141T1 (el) | 2017-10-10 | 2023-07-25 | Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (el) |
| EP (1) | EP3694863B1 (el) |
| JP (1) | JP7153069B2 (el) |
| KR (1) | KR102424621B1 (el) |
| CN (1) | CN111201235B (el) |
| AU (1) | AU2018349259B2 (el) |
| BR (1) | BR112020005989A2 (el) |
| CA (1) | CA3077508C (el) |
| CY (1) | CY1126141T1 (el) |
| DK (1) | DK3694863T3 (el) |
| ES (1) | ES2952985T3 (el) |
| FI (1) | FI3694863T3 (el) |
| HU (1) | HUE062926T2 (el) |
| MX (1) | MX2020003373A (el) |
| PL (1) | PL3694863T3 (el) |
| PT (1) | PT3694863T (el) |
| RU (2) | RU2022109286A (el) |
| SG (1) | SG11202002445SA (el) |
| SI (1) | SI3694863T1 (el) |
| TW (1) | TWI775960B (el) |
| WO (1) | WO2019073347A1 (el) |
| ZA (1) | ZA202001661B (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2972010T3 (es) | 2015-07-31 | 2024-06-10 | Pfizer | Forma cristalina de base libre de lorlatinib |
| WO2017175091A1 (en) | 2016-04-08 | 2017-10-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| EP3784675A1 (en) * | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013525476A (ja) | 2010-05-04 | 2013-06-20 | ファイザー・インク | Ａｌｋ阻害剤としての複素環式誘導体 |
| CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| LT2718257T (lt) * | 2011-06-08 | 2018-03-12 | Biogen Ma Inc. | Aukšto grynumo ir kristalinio dimetilfumarato gavimo būdas |
| JP5823066B2 (ja) * | 2012-03-06 | 2015-11-25 | ファイザー・インク | 増殖性疾患の治療のための大環状誘導体 |
| EP3013835B1 (en) * | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| CN107207528B (zh) * | 2014-08-20 | 2019-06-21 | 苏州韬略生物科技有限公司 | 作为激酶抑制剂的经取代大环及其使用方法 |
| ES2972010T3 (es) | 2015-07-31 | 2024-06-10 | Pfizer | Forma cristalina de base libre de lorlatinib |
| WO2017175091A1 (en) | 2016-04-08 | 2017-10-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
-
2018
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en unknown
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-04 BR BR112020005989-7A patent/BR112020005989A2/pt active Search and Examination
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active IP Right Grant
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 RU RU2020113141A patent/RU2020113141A/ru unknown
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3694863A1 (en) | 2020-08-19 |
| RU2020113141A3 (el) | 2021-11-12 |
| US20200308191A1 (en) | 2020-10-01 |
| CA3077508A1 (en) | 2019-04-18 |
| JP7153069B2 (ja) | 2022-10-13 |
| WO2019073347A1 (en) | 2019-04-18 |
| HUE062926T2 (hu) | 2023-12-28 |
| FI3694863T3 (fi) | 2023-08-18 |
| SI3694863T1 (sl) | 2023-10-30 |
| SG11202002445SA (en) | 2020-04-29 |
| ES2952985T3 (es) | 2023-11-07 |
| DK3694863T3 (da) | 2023-07-03 |
| JP2020536893A (ja) | 2020-12-17 |
| BR112020005989A2 (pt) | 2020-09-29 |
| RU2020113141A (ru) | 2021-11-12 |
| KR20200051781A (ko) | 2020-05-13 |
| PT3694863T (pt) | 2023-08-23 |
| RU2022109286A (ru) | 2022-05-06 |
| MX2020003373A (es) | 2020-10-12 |
| ZA202001661B (en) | 2023-11-29 |
| CN111201235B (zh) | 2023-02-10 |
| EP3694863B1 (en) | 2023-06-21 |
| KR102424621B1 (ko) | 2022-07-25 |
| AU2018349259A1 (en) | 2020-04-09 |
| US11299500B2 (en) | 2022-04-12 |
| PL3694863T3 (pl) | 2023-09-25 |
| AU2018349259B2 (en) | 2021-02-18 |
| CN111201235A (zh) | 2020-05-26 |
| TW201922753A (zh) | 2019-06-16 |
| CA3077508C (en) | 2023-02-14 |
| TWI775960B (zh) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1126141T1 (el) | Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης | |
| CY1123689T1 (el) | Κρυσταλλικη μορφη ελευθερης βασης λορλατινιβης | |
| CY1124068T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| CY1124206T1 (el) | Αναστολεις πυριδοπυριμδινονης cdk2/4/6 | |
| CY1121706T1 (el) | Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης | |
| CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1121195T1 (el) | Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1 | |
| CY1118771T1 (el) | Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων | |
| CY1123295T1 (el) | Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης | |
| EA201790766A1 (ru) | Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| CL2015002387A1 (es) | Nuevos derivados de pirazol. | |
| CY1119619T1 (el) | Παραγωγα πυριδιν-4-υλιου | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| CY1122439T1 (el) | Κυκλοαλκυλ-συνδεδεμενα παραγωγα δι-ετεροκυκλων | |
| EP4364741A3 (en) | Polymorphic form of tg02 | |
| CR20150456A (es) | Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen | |
| CY1121693T1 (el) | Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1 | |
| CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
| MX2018005785A (es) | Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos. | |
| CY1118570T1 (el) | Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| CY1122140T1 (el) | Μεθοδος παραγωγης φαρμακολογικως καθαρων κρυσταλλων | |
| CO6592046A2 (es) | 5-alquinil pirimidas y su uso como inhibidores de quinasa | |
| EA201990196A1 (ru) | Пиридопиримидиноновые ингибиторы cdk2/4/6 | |
| CR9988A (es) | Procedimiento para la preparación del inhibidor del ciclo celular-779 cristalino y purificado |